Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T124358 |
Deferoxamine
Deferoxamine B,Desferrioxamine B |
Apoptosis; Antioxidant; HIF; Autophagy | Angiogenesis; Apoptosis; Autophagy; Chromatin/Epigenetic; oxidation-reduction |
Deferoxamine(Desferrioxamine B) 是一种铁螯合剂 (结合 Fe(III) 和许多其他金属阳离子),可抑制神经元病变,可用于改减少铁在组织中的积累和沉积,可通过抑制创伤性脑损伤后的铁死亡和神经炎症来改善神经功能障碍。Desferrioxamin-B 具有抗氧化、抗增殖、抗肿瘤活性,可诱导 HIF-1α 产生,诱导癌细胞凋亡和自噬。Desferrioxamin-B 可用于治疗急性铁中毒和与 COVID-19 相关疾病。 | |||
T1637 |
Deferoxamine Mesylate
desferrioxamine B,Desferrioxamine B mesylate,DFO,DFOM,去铁铵,甲磺酸去铁胺 |
Mitophagy; Beta Amyloid; Others; Ferroptosis; HIF/HIF Prolyl-Hydroxylase; Autophagy | Apoptosis; Autophagy; Chromatin/Epigenetic; Metabolism; Neuroscience; Others |
Deferoxamine Mesylate (DFOM) 是一种铁螯合剂和铁死亡抑制剂。Deferoxamine Mesylate 可将游离铁结合成稳定的复合物,减少铁的积累。Deferoxamine Mesylate 可以上调 HIF-1α 水平,诱导细胞凋亡。 | |||
T35994 |
Erastin2
Erastin2 |
||
Erastin2 is a ferroptosis inducer and an inhibitor of the system xc- cystine/glutamate transporter.[1] [2] It inhibits glutamate release in CCF-STTG1 cells (IC50 = 0.0035 µM).[2] It induces cell death in HAP1 cells when used at a concentration of 5 µM, an effect that can be blocked by the ferroptosis inhibitor ferrostatin-1 or deferoxamine . [1] Erastin2 also induces ferroptotic cell death in HT-1080 cells (EC50 = 0.15 µM), an effect that can be blocked by the reducing agent β-merc... | |||
T83871 |
Ferroptocide
|
||
Ferroptocide是一种抑制剂,可抑制硫氧还蛋白(Trx)活性,并且是pleuromutilin的衍生物。在20 µM的浓度下,Ferroptocide能够抑制ES-2卵巢癌细胞中的Trx活性,并对ES-2细胞具有细胞毒性(IC50 = 1.6 µM)。5 µM的Ferroptocide能够诱导ES-2细胞发生铁死亡,这一效应可以通过铁螯合剂去铁胺(DFO)、抗氧化剂Trolox或铁死亡抑制剂ferrostatin-1来阻断。在使用免疫完整但非免疫缺陷小鼠的4T1小鼠乳腺癌模型中,每周两次以50 mg/kg剂量给药时,Ferroptocide能够减少肿瘤体积。 |